Oragenics, Inc. Announces Closing of $13.8 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option July 17, 2018
Oragenics, Inc. Announces Peer-Reviewed Publication Detailing Discovery of OG716 for C. difficile infections June 13, 2018
Oragenics Reports Positive Interim Safety Analysis Results from Its Phase 2 Clinical Trial of AG013 for Oral Mucositis May 30, 2018
Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140 May 23, 2018
Oragenics Completes Enrollment for the Interim Analysis Cohort in Its Phase 2 Clinical Trial of AG013 for Oral Mucositis March 23, 2018
Oragenics, Inc. Announces Peer Reviewed Publication Examining Efficacy of Mutacin 1140 Lantibiotic Variants against Clostridium difficile March 19, 2018
